TIGAR and cervical carcinoma: These results suggest that therapeutically inhibiting TIGAR could make hrHPV-induced cervical cancers hypersensitive to low concentrations of etoposide and thereby reduce the potential for adverse side-effects associated with this chemotherapeutic agent.